Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial

被引：0

作者：

Helsten, Teresa L. ^{[1
]}

Lo, Shelly S. ^{[2
]}

Yau, Christina ^{[3
]}

Kalinsky, Kevin ^{[4
]}

Elias, Anthony D. ^{[5
]}

Wallace, Anne M. ^{[1
]}

Chien, A. Jo ^{[3
]}

Lu, Janice ^{[6
]}

Lang, Julie E. ^{[6
]}

Albain, Kathy S. ^{[2
]}

Stringer-Reasor, Erica ^{[7
]}

Clark, Amy S. ^{[8
]}

Boughey, Judy C. ^{[9
]}

Ellis, Erin D. ^{[10
]}

Yee, Douglas ^{[11
]}

DeMichele, Angela ^{[8
]}

Isaacs, Claudine ^{[12
]}

Perlmutter, Jane ^{[13
]}

Rugo, Hope S. ^{[3
]}

Schwab, Richard ^{[1
]}

Hylton, Nola M. ^{[3
]}

Symmans, W. Fraser ^{[14
]}

Melisko, Michelle E. ^{[15
]}

van't Veer, Laura J. ^{[3
]}

Wilson, Amy ^{[16
]}

Singhrao, Ruby ^{[3
]}

Asare, Smita M. ^{[16
]}

Sanil, Ashish ^{[17
]}

Berry, Donald A. ^{[14
]}

Esserman, Laura J. ^{[3
]}

机构：

[1] Univ Calif San Diego, La Jolla, CA 92093 USA

[2] Loyola Univ, Maywood, IL 60153 USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Columbia Univ, New York, NY USA

[5] Univ Colorado, Aurora, CO USA

[6] Univ Southern Calif, Los Angeles, CA 90007 USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Univ Penn, Philadelphia, PA USA

[9] Mayo Clin, Rochester, MN USA

[10] Swedish Canc Inst, Seattle, WA USA

[11] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA

[12] Georgetown Univ, Washington, DC USA

[13] Gemini Grp, Ann Arbor, MI USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[15] Univ Calif San Francisco, La Jolla, CA USA

[16] Quantum Leap Healthcare Collaborat, San Francisco, CA USA

[17] Berry Consultants LLC, Austin, TX USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P3-11-02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3-11-02

引用

页数：4

共 50 条

[31] PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Stringer-Reasor, Erica
Shatsky, Rebecca A.
Chien, Jo
Wallace, Anne
Boughey, Judy C.
Albain, Kathy S.
Han, Hyo S.
Nanda, Rita
Isaacs, Claudine
Kalinsky, Kevin
Mitri, Zahi
Clark, Amy S.
Vaklavas, Christos
Thomas, Alexandra
Trivedi, Meghna S.
Lu, Janice
Asare, Smita
Lu, Ruixiao
Pitsouni, Maria
Wilson, Amy
Perlmutter, Jane
Rugo, Hope
Schwab, Richard
Symmans, W. Fraser
Hylton, Nola M.
Van 't Veer, Laura
Yee, Douglas
DeMichele, Angela
Berry, Donald
Esserman, Laura J.
[J]. CANCER RESEARCH, 2023, 83 (05)
[32] Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer.
Colomer, R
Mayordomo, JI
Calvo, L
Hornedo, J
Carabantes, F
Gil, M
Martin, B
Cortes-Funes, H
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 61S - 61S
[33] Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial
Glas, A.
Peeters, J.
Yau, C.
Wolf, D. M.
Sanil, A.
Li, Y.
Severson, T.
Linn, S.
Buxton, M.
DeMichele, A.
Hylton, N.
Symmans, F.
Yee, D.
Paoloni, M.
Esserman, L.
Berry, D.
Rugo, H.
Olopade, O.
van 't Veer, L. J.
[J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 173 - 173
[34] HER2 ECD-positive metastatic breast cancer treated with gemcitabine, paclitaxel plus trastuzumab (GTH)
Colomer, R
Mayordomo, JI
Calvo, L
Hornedo, J
Carabantes, F
Gil, M
Cortes-Funes, H
Martin, B
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S127 - S128
[35] Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer
Hyams, D. M.
Leichman, G. C.
Klein, P.
Rietchsel, P.
Levine, E. G.
Gebski, V. J.
Kelley, M. A.
[J]. CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
[36] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer
Jinno, H.
Sato, T.
Takahashi, M.
Hayashida, T.
Sakata, M.
Hirose, S.
Kitagawa, Y.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[37] A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
Adrienne G. Waks
Neelam V. Desai
Tianyu Li
Philip D. Poorvu
Ann H. Partridge
Natalie Sinclair
Laura M. Spring
Meredith Faggen
Michael Constantine
Otto Metzger
Jillian Alberti
Julia Deane
Shoshana M. Rosenberg
Elizabeth Frank
Sara M. Tolaney
Ian E. Krop
Nadine M. Tung
Nabihah Tayob
Tari A. King
Elizabeth A. Mittendorf
Eric P. Winer
[J]. npj Breast Cancer, 8
[38] A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
Waks, Adrienne G.
Desai, Neelam V.
Li, Tianyu
Poorvu, Philip D.
Partridge, Ann H.
Sinclair, Natalie
Spring, Laura M.
Faggen, Meredith
Constantine, Michael
Metzger, Otto
Alberti, Jillian
Deane, Julia
Rosenberg, Shoshana M.
Frank, Elizabeth
Tolaney, Sara M.
Krop, Ian E.
Tung, Nadine M.
Tayob, Nabihah
King, Tari A.
Mittendorf, Elizabeth A.
Winer, Eric P.
[J]. NPJ BREAST CANCER, 2022, 8 (01)
[39] I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer
Wang, Haiyun
Yee, Douglas
[J]. CURRENT BREAST CANCER REPORTS, 2019, 11 (04) : 303 - 310
[40] Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
Ricciardi, Giuseppina Rosaria Rita
Franchina, Tindara
Russo, Alessandro
Schifano, Silvia
Ferraro, Giuseppa
Adamo, Vincenzo
[J]. ONCOTARGETS AND THERAPY, 2016, 9 : 4351 - 4355

← 1 2 3 4 5 →